Fieke Terstappen

Ms. Fieke Terstappen

Department of Developmental Origins of Disease (DDOD) and Obstetrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Hypertension
Verified
Journal Article
Open access
PDF file
NPNina D. Paauw
Nina D. Paauw
FTFieke Terstappen
Fieke Terstappen
WGWessel Ganzevoort
Wessel Ganzevoort
JJJaap A. Joles
Jaap A. Joles
HGHendrik Gremmels
Hendrik Gremmels
ALA. Titia Lely
A. Titia Lely
Sildenafil is a new approach to treat fetal growth restriction (FGR) and preeclampsia. We performed a systematic meta-analysis to evaluate effects of sildenafil. Our search identified 22 animal studies (mouse, rat, rabbit, sheep, and guinea pigs) and 2 human randomized controlled trials. Data were pooled using ratio of means and mean differences with 95% confidence intervals for fetal growth and maternal blood pressure, respectively. Meta-regression analyses were performed for study-related factors that might affect efficacy of sildenafil, including the model used (healthy pregnancy versus FGR/preeclampsia) and route of administration. Dose–response curves with dose per metabolic weight (mg/kg 0.75 per 24 hours) were fitted using splines. Our analyses show that sildenafil increases fetal growth during FGR/preeclampsia pregnancy compared with healthy pregnancy (1.10 [1.06–1.13] versus 1.03 [0.99–1.06]; P =0.006). There was no significant effect on fetal growth in the absence of FGR/preeclampsia. Effects were similar among different species and largest after oral and continuous administration. There was a positive relation between dose and fetal growth up to a human equivalent dose of ≈450 mg/d. A significant blood pressure–lowering effect of sildenafil is present during FGR/preeclampsia pregnancy only (−19 [−25 to −13] mm Hg; P <0.01), with the effect size being highly dependent on baseline blood pressure and without effect in the absence of hypertension. This meta-analysis supports that sildenafil improves fetal growth and maternal blood pressure regulation during FGR and preeclampsia pregnancy. The greatest beneficial effects on fetal growth are with dosages greater than those currently used in human studies.

21 August 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
FTFieke Terstappen
Fieke Terstappen
ATAngela Tol
Angela Tol
HGHendrik Gremmels
Hendrik Gremmels
KWKimberley E. Wever
Kimberley E. Wever
NPNina D. Paauw
Nina D. Paauw
ALA. Titia Lely
A. Titia Lely
Aberrant fetal growth remains a leading cause of perinatal morbidity and mortality and is associated with a risk of developing non-communicable diseases later in life. We performed a systematic review and meta-analysis combining human and animal studies to assess whether prenatal amino acid (AA) supplementation could be a promising approach to promote healthy fetal growth. PubMed, Embase, and Cochrane libraries were searched to identify studies orally supplementing the following AA groups during gestation: (1) arginine family, (2) branched chain (BCAA), and (3) methyl donors. The primary outcome was fetal/birth weight. Twenty-two human and 89 animal studies were included in the systematic review. The arginine family and, especially, arginine itself were studied the most. Our meta-analysis showed beneficial effects of arginine and (N-Carbamyl) glutamate (NCG) but not aspartic acid and citrulline on fetal/birth weight. However, no effects were reported when an isonitrogenous control diet was included. BCAA and methyl donor supplementation did not affect fetal/birth weight. Arginine family supplementation, in particular arginine and NCG, improves fetal growth in complicated pregnancies. BCAA and methyl donor supplementation do not seem to be as promising in targeting fetal growth. Well-controlled research in complicated pregnancies is needed before ruling out AA supplements or preferring arginine above other AAs.

1 May 2019 in Hypertension
Verified
Journal Article
Closed access
PDF file
FTFieke Terstappen
Fieke Terstappen
FSFrank T. Spradley
Frank T. Spradley
BBBhavisha A. Bakrania
Bhavisha A. Bakrania
SCSinéad M. Clarke
Sinéad M. Clarke
JJJaap A. Joles
Jaap A. Joles
JSJennifer M. Sasser
Jennifer M. Sasser
Fetal growth restriction (FGR) is associated with increased risk for cardiovascular and renal disorders in later life. Prenatal sildenafil improves birth weight in FGR animal models. Whether sildenafil treatment protects against long-term cardiovascular and renal disease in these offspring is unknown. The aim of this study is to test the hypothesis that prenatal sildenafil ameliorates cardiovascular and renal function in FGR offspring of Dahl salt-sensitive rats. Sildenafil citrate (60 mg/kg per day) or control gel diet (containing 0.3% salt) was administered from gestational day ten until birth. In male and female offspring, the mean arterial pressure was measured by telemetry in 1 subset from week 5 until week twenty. Echocardiographic parameters, glomerular filtration rate, and fractional electrolyte excretion were determined in another subset at week 9. Aortic and mesenteric artery rings were prepared to assess endothelial-dependent (acetylcholine) and -independent (sodium nitroprusside) vasorelaxation (week 10). The rise in mean arterial pressure per week was attenuated in treated versus untreated male offspring. Mesenteric arteries showed an increased endothelium-dependent relaxation and improved endothelium-independent relaxation in treated versus control male offspring. No differences in aortic relaxation, echocardiographic parameters or renal function were observed between groups. Prenatal sildenafil treatment subtly improves cardiovascular but not renal function in the offspring of this FGR rat model. Translationally, in utero treatment could be beneficial for cardiovascular programming in a sex-specific manner; however, caution is warranted since recent human trials have been halted because of potentially deleterious neonatal side effects when treating pregnancies complicated with severe FGR with sildenafil.

1 July 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
CKCaren M. van Kammen
Caren M. van Kammen
STSeija E. L. Taal
Seija E. L. Taal
KWKimberley E. Wever
Kimberley E. Wever
JGJoey P. Granger
Joey P. Granger
ALA. Titia Lely
A. Titia Lely
FTFieke Terstappen
Fieke Terstappen
The reduced uterine perfusion pressure (RUPP) model is frequently used to study preeclampsia and fetal growth restriction. An improved understanding of influential factors might improve reproducibility and reduce animal use considering the variability in RUPP phenotype. We performed a systematic review and meta-analysis by searching Medline and Embase (until 28 March, 2023) for RUPP studies in murine. Primary outcomes included maternal blood pressure (BP) or proteinuria, fetal weight or crown-rump length, fetal reabsorptions, or antiangiogenic factors. We aimed to identify influential factors by meta-regression analysis. We included 155 studies. Our meta-analysis showed that the RUPP procedure results in significantly higher BP (MD = 24.1 mmHg; [22.6; 25.7]; n = 148), proteinuria (SMD = 2.3; [0.9; 3.8]; n = 28), fetal reabsorptions (MD = 50.4%; [45.5; 55.2]; n = 42), circulating soluble FMS-like tyrosine kinase-1 (sFlt-1) (SMD = 2.6; [1.7; 3.4]; n = 34), and lower fetal weight (MD = −0.4 g; [−0.47; −0.34]; n = 113. The heterogeneity (variability between studies) in primary outcomes appeared ≥90%. Our meta-regression identified influential factors in the method and time point of BP measurement, randomization in fetal weight, and type of control group in sFlt-1. The RUPP is a robust model considering the evident differences in maternal and fetal outcomes. The high heterogeneity reflects the observed variability in phenotype. Because of underreporting, we observed reporting bias and a high risk of bias. We recommend standardizing study design by optimal time point and method chosen for readout measures to limit the variability. This contributes to improved reproducibility and thereby eventually improves the translational value of the RUPP model.

14 February 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
FTFieke Terstappen
Fieke Terstappen
SCSinéad M. Clarke
Sinéad M. Clarke
Jaap JolesJaap Joles
Jaap Joles
CRCourtney A Ross
Courtney A Ross
MGMichael Garrett
Michael Garrett
ALA. Titia Lely
A. Titia Lely
Aberrant production of hydrogen sulfide (H2S) has been linked to preeclampsia. We hypothesized that sodium thiosulfate (STS), a H2S donor, reduces hypertension and proteinuria, and diminishes fetal growth restriction in the Dahl salt-sensitive (S) rat, a spontaneous model of superimposed preeclampsia. In addition to a control group (n = 13), two groups received STS via drinking water at a dose of 2 g (n = 9) or 3 g per kg body weight per day (n = 8) from gestational day (GD) 10 to 20. Uterine artery resistance index was measured (GD18), urinary protein excretion rate was determined (GD19), and blood pressure and fetal outcomes were evaluated (GD20). At 2 g, STS had no effect on preeclamptic symptoms or fetal outcome. At 3 g, STS reduced maternal hypertension (121.8 ± 3.0 vs. 136.3 ± 2.9), but increased proteinuria (89 ± 15 vs. 56 ± 5 mg/24 h), and relative kidney weight (0.86 ± 0.04 vs. 0.73 ± 0.02%). Fetal/placental weight ratio was reduced (3.83 ± 0.07 vs. 4.31 ± 0.08) without affecting litter size. No differences in uterine artery flow or renal histological damage were noted across treatment groups. While these data suggest a promising antihypertensive effect that could imply prolongation of preeclamptic pregnancies, the unfavorable effects on proteinuria, kidney weight, and fetal/placental weight ratio implies that clinical implementation of STS is contra-indicated until safety for mother and child can be verified.

20 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FTFieke Terstappen
Fieke Terstappen
NPNina D Paauw
Nina D Paauw
TAThomas Alderliesten
Thomas Alderliesten
JJJaap A Joles
Jaap A Joles
DVDaniel C Vijlbrief
Daniel C Vijlbrief
PLPetra M A Lemmers
Petra M A Lemmers
Fetal growth restriction (FGR) is associated with an increased risk for kidney disease in later life. Studies reporting on early signs of renal disturbances in FGR are sparse and mostly include invasive measurements, which limit the possibility for early identification and prevention. We aim to investigate whether renal tissue oxygen saturation (rSO2) measured with near-infrared spectroscopy (NIRS) and the derived value fractional tissue oxygen extraction (FTOE) differ between premature FGR and control neonates in the first three days after birth. Nine FGR and seven control neonates born <32 weeks of gestation were included. FGR was defined as biometry <p10 combined with prenatal signs of placental insufficiency. Renal rSO2 was measured continuously with NIRS for 72 hours. FTOE was calculated as: (arterial saturation-rSO2)/arterial saturation. Renal artery blood flow (pulsatility and resistance index) was measured within 24 hours after birth. A linear mixed model approach was used (intercept ± slope = r) to analyze the NIRS parameters. Renal rSO2 was higher in FGR neonates compared to controls (94% vs. 83%; pgroup = 0.002). During the first three days after birth, renal rSO2 decreased in FGR neonates and increased in controls (r = -0.25 vs. r = 0.03; pinteraction = 0.001). Renal FTOE was lower in FGR neonates (0.02 vs. 0.14; pgroup = 0.01) and increased slightly during three days after birth, while it remained stable in controls (r = 0.003 vs. r = -0.0001; pinteraction = 0.001). Renal artery blood flow was similar between groups. FGR neonate kidneys showed higher rSO2 as measured with NIRS and lower derived values of FTOE in the first three days after birth. We speculate that this was caused by either a reduced oxygen consumption due to impaired renal maturation or increased renal oxygen supply. How these observations correlate with short- and long-term renal function needs further investigation before renal NIRS can be implemented in screening and prevention in clinical practice.